GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020

Date: November 1, 2011
Pages: 32
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GD1CA27EDDBEN
Leaflet:

Download PDF Leaflet

GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020
GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020” provides GV1001 sales forecasts for the UK. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Pancreatic Cancer market.
This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the UK
  • Analysis and review of GV1001 including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of GV1001 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2014-2020 for GV1001 in the UK


Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Pancreatic Cancer
2.2 Pancreatic Cancer Market
2.3 Epidemiology
2.4 Etiology
  2.4.1 Cigarette Smoking
  2.4.2 Age
  2.4.3 Gender
  2.4.4 Family History
  2.4.5 Other Factors
2.5 GlobalData Report Guidance

3 PANCREATIC CANCER: MARKET CHARACTERIZATION

3.1 Pancreatic Cancer Disease Market
3.2 Pancreatic Cancer Disease Market Forecasts and CAGR
3.3 Drivers for the Pancreatic Cancer Disease Market
  3.3.1 High Incidence
  3.3.2 High Mortality Rate
  3.3.3 Large Unmet Need
  3.3.4 Pipeline Drugs

4 TUMOR-NODE-METASTASES (TNM) CLASSIFICATION OF PANCREATIC CANCER

5 GV1001

5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of GV1001
  5.4.1 Efficacy and Safety of GV1001
  5.4.2 Orphan Drug Status in the US and EU
  5.4.3 Launch of GV1001 in the US and Japan
  5.4.4 Competition
  5.4.5 Termination of PrimoVax Study
  5.4.6 Commercialization Capabilities of the Company
  5.4.7 Off Label Usage
5.5 Drug Evaluation
  5.5.1 Drug Risk Benefit Score
  5.5.2 Intensity of Competition
5.6 Sales Forecasts
  5.6.1 Target Patient Pool of GV1001
  5.6.2 Sales Forecasts of GV1001

6 APPENDIX

6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Forecasting
  6.3.4 Number of Patients Approved to take the Drug
  6.3.5 Net Penetration of Drug
  6.3.6 Net Annual Dosing
  6.3.7 Annual Cost of Therapy
  6.3.8 Primary Research
  6.3.9 Expert Panels
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

LIST OF TABLES

Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008–2030
Table 2: Pancreatic Cancer, TNM Classification
Table 3: Drug Risk Benefit Score of GV1001
Table 4: GV1001, Pancreatic Cancer, EU-5, Sales Forecasts ($m), 2014–2020
Table 5: GV1001, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2014–2020
Table 6: GV1001, Pancreatic Cancer, France, Sales Forecasts ($m), 2014–2020
Table 7: GV1001, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2014–2020
Table 8: GV1001, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2014–2020
Table 9: GV1001, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2014–2020

LIST OF FIGURES

Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008
Figure 2: Total number of cigarettes consumed, The US, 1976-2006
Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992–2007
Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010–2030
Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2009–2020
Figure 6: Pancreatic Cancer, Worldwide, Incidence (in million), 2008-2030
Figure 7: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 8: Pancreatic Cancer, Worldwide, Mortality (in millions), 2008-2030
Figure 9: Broad Classification of Pancreatic Cancer
Figure 10: Classification of Pancreatic Cancer
Figure 11: Drug Model Diagram of GV1001
Figure 12: GV1001, Pancreatic Cancer, EU-5, Sales Forecasts ($m), 2014–2020
Figure 13: GV1001, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2014–2020
Figure 14: GV1001, Pancreatic Cancer, France, Sales Forecasts ($m), 2014–2020
Figure 15: GV1001, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2014–2020
Figure 16: GV1001, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2014–2020
Figure 17: GV1001, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2014–2020
Figure 18: GV1001, Pancreatic Cancer, EU-5, Sales Distribution (%), 2020
Figure 19: Drug Model Diagram
Figure 20: Patients Approved for the Drug

Ask Your Question

GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: